Insights from Hematology Expert | Dr. Jianxiang Wang: Delving into Immune Mechanisms to Pioneer New Target Frontiers

Insights from Hematology Expert | Dr. Jianxiang Wang: Delving into Immune Mechanisms to Pioneer New Target Frontiers

The breakthrough achievements of CAR-T therapy in the field of hematologic malignancies are remarkable. However, challenges such as target limitations, limited cell sources, and durability of efficacy continue to necessitate further exploration. Dr. Jianxiang Wang's team at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , stands as a pioneer in the field of immunotherapy, advancing both basic and clinical research to push the boundaries of hematologic cancer immunotherapy. In this issue of Hematology Frontier, Dr. Jianxiang Wang shares the research outcomes and forward-looking insights of his team in the realm of immunotherapy. The aim is to inspire new clinical thinking and collaboratively open a new chapter in hematologic cancer immunotherapy, bringing more hope and possibilities to patients.
Dr. Ruiyun Zhang: New Approaches Like Targeted Immunotherapy and ctDNA Further Address the Bladder-Preserving Needs of MIBC Patients | 2024 ASCOBT

Dr. Ruiyun Zhang: New Approaches Like Targeted Immunotherapy and ctDNA Further Address the Bladder-Preserving Needs of MIBC Patients | 2024 ASCOBT

The ASCO Breakthrough Summit, held from August 8th to 10th in Yokohama, Japan, focused on new technologies in cancer treatment and shared breakthrough advances and research that are driving global cancer treatment forward. The research titled "Preliminary results of an open-label, single-arm, multi-center study on disitamab vedotin (DV) combined with toripalimab and radiotherapy as bladder-preserving therapy in HER2 overexpression muscle-invasive bladder cancer (MIBC; DECIDING study-stage I)" by Dr. Haige Chen and Dr. Ruiyun Zhang from Renji Hospital, Shanghai JiaoTong University School of Medicine, was selected for presentation. Urology Frontier invited Dr. Ruiyun Zhang to discuss the treatment needs of MIBC patients, the DECIDING study results, progress in ctDNA, and the team's ongoing explorations.
Dr. Erlie Jiang: Exploring Stem Cell Transplantation Strategies for Adult Acute Lymphoblastic Leukemia |The 8th CSCO Hematology Academic Conference

Dr. Erlie Jiang: Exploring Stem Cell Transplantation Strategies for Adult Acute Lymphoblastic Leukemia |The 8th CSCO Hematology Academic Conference

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss the frontier topic of hematopoietic stem cell transplantation (HSCT).
Dr. Jun Ma: Gathering Global Experts to Discuss Cutting-Edge Advances and Core Concepts | The 8th CSCO Annual Hematology Conference

Dr. Jun Ma: Gathering Global Experts to Discuss Cutting-Edge Advances and Core Concepts | The 8th CSCO Annual Hematology Conference

In the sweltering summer, we gather in Ice City. The “8th Annual Hematology Conference” organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the CSCO Lymphoma Expert Committee, and hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. Renowned experts and scholars from both domestic and international arenas came together to present and discuss research in leukemia, lymphoma, and myeloma, as well as address hot topics in clinical practice. On the first day of the conference, we were honored to interview Dr. Jun Ma, the conference chairman and director of the Harbin Institute of Hematology and Oncology, to share the hi
Professor Qian Jiang: Exploring New Models of Regional Academic Exchange, Beijing Hematology Academic Annual Meeting Concludes Successfully

Professor Qian Jiang: Exploring New Models of Regional Academic Exchange, Beijing Hematology Academic Annual Meeting Concludes Successfully

On July 5th, the 17th Beijing Hematology Academic Annual Meeting, hosted by the Beijing Medical Association Hematology Branch, concluded successfully in Beijing. This year's meeting featured innovative and unique formats and rich content, providing a platform for participants to share cutting-edge advancements and experiences. It also showcased the original research achievements in the field of hematology in Beijing. "Oncology Frontier - Hematology Frontier" invited Professor Qian Jiang, the current chair of the Beijing Medical Association Hematology Branch, the main organizer of this conference, and a professor at Peking University People's Hospital, to share the highlights and unique aspects of the meeting and to discuss its far-reaching impacts on the future.
Dr. He Huang: Focusing on the Rise and Challenges of Cellular Immunotherapy | The 8th CSCO Hematology Academic Conference

Dr. He Huang: Focusing on the Rise and Challenges of Cellular Immunotherapy | The 8th CSCO Hematology Academic Conference

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held grandly in Harbin from July 26 to 28. The conference aimed to provide an important platform for in-depth learning and extensive exchange among experts and scholars in the field of hematological tumors. On this occasion, "Oncology Frontier - Hematology Frontier" specially invited Dr. He Huang from The First Affiliated Hospital , Zhejiang University School of Medicine to discuss the frontier topic of cellular immunotherapy.
Dr. Zhixiang Shen: Ten Years of Transformative Ideas in Hematological Oncology – From Treatment to Management

Dr. Zhixiang Shen: Ten Years of Transformative Ideas in Hematological Oncology – From Treatment to Management

In the scorching summer, experts gathered in the cool city of Harbin for the 8th Hematology Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital. Held from July 26 to 28, 2024, this grand event brought together renowned experts and scholars from home and abroad to present on leukemia, lymphoma, and myeloma, sharing research findings and practical experiences. "Oncology Frontier - Hematology Frontier" had the honor of interviewing Dr. Zhixiang Shen, chairman of this conference and a professor at Ruijin Hospital, Shanghai JiaoTong University School of Medicine. He discussed the highlights of the conference, the current status of indolent lymphoma diagnosis and treatment, the concept of chronic disease management in hematological oncology, and future trends in the field.
Dr. Jing Sun: SYK Inhibitors Set Sail at EHA – Solepinib’s Dual Mechanism Offers New Hope for ITP Treatment

Dr. Jing Sun: SYK Inhibitors Set Sail at EHA – Solepinib’s Dual Mechanism Offers New Hope for ITP Treatment

The annual meeting of the European Hematology Association (EHA) is an international conference in the field of hematology, bringing together numerous experts and scholars from around the world to share and delve into innovative ideas and research progress, promoting continuous development in the field of hematology. This year, the research achievements of spleen tyrosine kinase (SYK) inhibitors attracted significant attention. HMPL-523 (Solepinib), the first SYK inhibitor from China to apply for market approval (*as of the press date), presented multiple research results at the EHA conference. In this issue, "Oncology Frontier - Hematology Frontier" invited Dr. Jing Sun from the Department of Hematology at Nanfang Hospital, Southern Medical University, to provide an in-depth interpretation of the ESLIM-01 study (NCT05029635) on Solepinib in the treatment of primary immune thrombocytopenia (ITP), aiming to offer clinical practice insights.